Table 1 Baseline characteristics of the AS study population
| Â | Total | IFX | ETA | ADA |
|---|---|---|---|---|
Number of patients | 220 | 32 | 137 | 51 |
Age (yrs) | 42.9 ± 11.9 | 45.8 ± 10.1 | 41.9 ± 11.6 | 43.7 ± 13.3 |
Gender (male) (n, %) | 152 (69) | 20 (63) | 96 (70) | 36 (71) |
Duration of symptoms (yrs) | 15 (1 to 53) | 21 (2 to 49) | 15 (1 to 47) | 11 (1 to 53) |
Time since diagnosis (yrs) | 7 (0 to 45) | 16 (0 to 35)* | 7 (0 to 44) | 6 (0 to 45) |
HLA-B27+ (n, %) | 174 (81) | 24 (75) | 108 (82) | 42 (82) |
History of IBD (n, %) | 20 (9) | 8 (26)†| 7 (5) | 4 (8) |
History of uveitis (n, %) | 64 (29) | 13 (40) | 44 (32) | 7 (14)‡ |
History of psoriasis (n, %) | 13 (6) | 3 (9) | 8 (6) | 13 (6) |
Peripheral arthritis (n, %) | 37 (17) | 5 (16) | 27 (20) | 5 (10) |
Current NSAID use (n, %) | 158 (72) | 24 (75) | 102 (75) | 32 (63) |
Current DMARD use (n, %) | 45 (21) | 10 (31) | 28 (20) | 7 (14) |
BASDAI (range 0 to 10) | 6.1 ± 1.7 | 6.1 ± 1.4 | 6.2 ± 1.7 | 5.9 ± 1.7 |
ASDAS | 3.8 ± 0.8 | 3.8 ± 0.6 | 3.8 ± 0.8 | 3.7 ± 0.9 |
Physician's GDA (range 0-10) | 5 (0 to 9) | 5 (0 to 8) | 5 (0 to 9) | 3 (0 to 9)‡ |
Patient's GDA (range 0 to 10) | 7 (1 to 10) | 6 (1 to 9) | 7 (1 to 10) | 6 (1 to 10) |
ESR (mm/h) | 21 (2 to 101) | 24 (2 to 90) | 20 (2 to 101) | 23 (2 to 74) |
CRP (mg/l) | 13 (2 to 99) | 15 (2 to 74) | 12 (2 to 99) | 14 (2 to 92) |
BASFI (range 0 to 10) | 6.1 (0.3 to 9.7) | 6.3 (1.9 to 9.6) | 5.9 (0.3 to 9.7) | 6.3 (0.4 to 9.5) |
Chest expansion (cm) | 3.0 (0.5 to 43.0) | 2.5 (0.5 to 7.0) | 3.0 (0.5 to 22.0) | 3.5 (0.0 to 43.0)§ |
Modified Schober test (cm) | 2.9 (0.0 to 7.0) | 2.4 (0.5 to 6.0) | 2.8 (0.1 to 7.0) | 3.2 (0.0 to 5.5) |
Occiput to wall distance (cm) | 4.9 (0.0 to 34.5) | 9.0 (0.0 to 26.0)^ | 4.5 (0.0 to 34.5) | 3.5 (0.0 to 30.0) |
Lateral lumbar flexion L (cm) | 8.0 (0.0 to 30.0) | 7.0 (2.0 to 15.0) | 9.0 (0.0 to 30.0) | 8.0 (1.0 to 20.5) |
Lateral lumbar flexion R (cm) | 8.0 (0.0 to 29.0) | 8.0 (0.5 to 17.0) | 8.0 (0.0 to 29.0) | 7.5 (1.0 to 20.0) |